Amgen Inc. (NASDAQ:AMGN) Shares Sold by Xponance Inc.

Xponance Inc. lessened its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 2.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 116,362 shares of the medical research company's stock after selling 2,346 shares during the quarter. Xponance Inc.'s holdings in Amgen were worth $30,329,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Centricity Wealth Management LLC acquired a new position in Amgen in the 4th quarter valued at about $25,000. Legacy Investment Solutions LLC acquired a new position in Amgen in the 3rd quarter valued at about $29,000. Synergy Investment Management LLC acquired a new position in Amgen in the 4th quarter valued at about $34,000. Atala Financial Inc acquired a new position in Amgen in the 4th quarter valued at about $34,000. Finally, Heck Capital Advisors LLC acquired a new position in Amgen in the 4th quarter valued at about $36,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Stock Up 0.3 %

Amgen stock traded up $1.00 during midday trading on Friday, hitting $316.04. 9,994,350 shares of the company were exchanged, compared to its average volume of 2,552,453. The company's fifty day moving average price is $297.24 and its 200-day moving average price is $299.02. The company has a market cap of $169.78 billion, a PE ratio of 41.86, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85.

Remove Ads

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, research analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.01%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's payout ratio is 126.09%.

Analysts Set New Price Targets

Several brokerages recently weighed in on AMGN. Deutsche Bank Aktiengesellschaft cut their target price on shares of Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. Wells Fargo & Company reissued an "equal weight" rating on shares of Amgen in a research note on Wednesday, February 5th. Royal Bank of Canada restated an "outperform" rating and issued a $324.00 price target on shares of Amgen in a report on Friday, January 24th. Truist Financial lowered their price target on Amgen from $333.00 to $298.00 and set a "hold" rating for the company in a report on Wednesday, January 8th. Finally, StockNews.com cut Amgen from a "strong-buy" rating to a "buy" rating in a report on Wednesday, December 18th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $314.04.

Insider Buying and Selling at Amgen

In other Amgen news, EVP Jonathan P. Graham sold 25,045 shares of the company's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $293.12, for a total value of $7,341,190.40. Following the transaction, the executive vice president now directly owns 28,987 shares of the company's stock, valued at $8,496,669.44. This represents a 46.35 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Nancy A. Grygiel sold 1,589 shares of the company's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock valued at $20,644,335 in the last three months. Corporate insiders own 0.69% of the company's stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.